Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
about
B-cell survival factors in autoimmune rheumatic disordersLupus nephritis: the evolving role of novel therapeuticsReviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatmentRituximab in primary Sjögren's syndrome: a ten-year journey.BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) miceCurrent and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateB-cell hyperactivity in primary Sjögren's syndrome.B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis.Current and Emerging Therapies for Lupus Nephritis.Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro.PD-L1hi B cells are critical regulators of humoral immunity.Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.Acquisition of N-Glycosylation Sites in Immunoglobulin Heavy Chain Genes During Local Expansion in Parotid Salivary Glands of Primary Sjögren Patients.The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome
P2860
Q26796484-DB896625-FB5C-4911-BE08-0757BA669C96Q26998390-CCD9855D-68EA-4DA7-B9DB-16A48129EE47Q30234992-6CB91BD5-1227-4EEB-9B50-C897C3C97C2BQ34432465-26AC7CBE-3BF1-4F53-9070-E75C7D465FEBQ34656412-920457FF-53DC-4547-BA79-1160ABC412FEQ34960458-E7EC7F86-D5A8-45FE-82A5-059D485A0A90Q36106681-1247F071-E9F9-4E7F-82B3-45B368C27FB6Q37690012-EA30CC91-0D06-49CF-8C29-041DB4BD0C66Q37691074-3444F3F0-2B29-476C-B667-C639A1454BD3Q37709763-DA77B87C-8ACB-493F-8CDC-6965701107A1Q38190590-505346F4-11DA-4037-A9D8-B2ECCBC78F30Q38371009-F2C49EFF-B624-4C20-9865-10F668E5B3DFQ38855495-12E2D152-F866-476E-9076-52B10E8FBFC7Q40593657-D03DC1D0-852D-4B62-8BC6-3E9000FFB866Q41529474-E0A3200B-BA8A-4A53-9D92-4B6B9963290AQ45754988-EE87A62C-98E1-4CBA-AB18-D8FF85CA60F5Q55125041-1257FF7F-0E03-4591-8425-DEA2C8E15FD9Q55970269-F3729AB0-6A8C-4ADC-8CE1-D57FDEFF9E93
P2860
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@en
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@nl
type
label
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@en
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@nl
prefLabel
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@en
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@nl
P2093
P1476
Serum levels of BAFF, but not ...... ebo-controlled clinical trial.
@en
P2093
Annie Visser
Arjan Vissink
Frans G M Kroese
Fred K L Spijkervet
Hendrika Bootsma
Jiska M Meijer
Johannes G M Burgerhof
Minke G Huitema
Nishath Hamza
Rodney P E Pollard
P304
P356
10.1136/ANNRHEUMDIS-2012-202071
P407
P577
2012-07-31T00:00:00Z